Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment
You may not be if
Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
Participation in a clinical trial at baseline and during the follow-up period
Clareo Health | Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
